ClinicalTrials.gg
Not yet recruitingNCT07570953Updated Sep 18, 2026

A Study Of Synthetic THC And Sleep

A Phase 2/3 interventional study of Dronabinol and Placebo in Obstructive Sleep Apnea, sponsored by Mayo Clinic. Not yet recruiting at 1 site in United States. Open to participants aged 21 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-09-18.

Sponsored by Mayo Clinic · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
21 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Sleep Apnea, Obstructive by Mayo Clinic — 6 open to participants now, 6 under way, 1 of them phase 3. Sleep Apnea, Obstructive · Mayo Clinic.

Planned enrollment
Largest of 11
72 · median 43
Started
2026
the only one that year
Phase 2/3
Only one
of the 17
Registered
17th of 17
by date

Among the 17 studies in Sleep Apnea, Obstructive by Mayo Clinic, this one has the largest planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2026, is the only one in phase 2/3, and was the 17th registered.

Sleep Apnea, Obstructive

2,243 studies on the registry are indexed under Sleep Apnea, Obstructive; 475 are open to participants now.

Browse Sleep Apnea, Obstructive studies →

Open to participants now

6 of the 17 studies in Sleep Apnea, Obstructive by Mayo Clinic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 313 Sleep Apnea, Obstructive studies recruiting now, 146 (47%) set no upper age limit and 124 (40%) stop at 75 or younger; 52 take children under 18; 65 take healthy volunteers.

This study: 21 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Sleep Apnea, Obstructive by Mayo Clinic, or all of them as a file.
02

Study summary

The purpose of this study is to determine if oral dronabinol prior to sleep can improve CPAP adherence and sleep quality in humans. We also seek to determine if combination therapy of CPAP and pre-sleep dronabinol is associated with improved BP regulation. We will also explore BP regulatory mechanisms and whether these are impacted differently between traditional CPAP therapy and combination CPAP/dronabinol.

03

Conditions studied

  • Obstructive Sleep Apnea
04

Who can participate

Ages eligible
21 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 21 - 70 years of age
  • Biological male or female
  • AHI between 15 - 50 events/hour
  • Current or new OSA diagnosis
  • Established or new (within 1 month) CPAP therapy

Exclusion criteria

Exclusion Criteria

  • > 35 kg/m2
  • Diagnosed psychiatric disorders
  • Hypotension
  • History of seizures
  • History of substance abuse or recreational drug use or positive urine drug screen
  • History of uncontrolled disease including:

    • Cardiovascular
    • Pulmonary
    • Gastrointestinal
    • Pancreatic
    • Hepatic
    • Renal
    • Hematological
    • Endocrine (including Type I Diabetes)
    • Neurological
    • Urological
  • Pregnant or breastfeeding
  • Use of certain antimicrobial, chemotherapeutic, anticoagulant, hypoglycemic, anti-inflammatory, psychotropic, and antihistamine drugs
  • Prescribed CYP2C9 and/or inhibitors
  • Severe OSA that in the investigator's judgment should only begin CPAP treatment
  • Prior upper airway surgery for snoring or OSA as an adult
  • Significant defect in nasal patency due to anatomical abnormality or uncontrolled rhinitis
  • Bariatric surgery within 2 years
  • Medically managed weight-loss program within 6 months
  • Noninvasive treatment for OSA within 1 month (self-report)
  • History of shift work or rotating shifts within 1 month
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    Dronabinol

    Patients assigned to the Dronabinol arm will be taking the Study drug (Dronabinol) one hour prior to bed each night for 6 weeks.

    Drug: Dronabinol

  • Placebo comparator
    Placebo

    Patients assigned to the placebo arm will be taking the placebo pill (sugar pill) one hour prior to bed each night for 6 weeks.

    Drug: Placebo

Interventions

  • 10 mg dose of Dronabinol daily for 6 weeks

  • DrugPlacebo

    10 mg dose of Placebo daily for 6 weeks

06

What researchers measure

Primary outcomes

  1. Number of times subjects complete CPAP therapy

    CPAP therapy is defined as using the therapeutic device for ≥ 4 hours per night

    Time frame: Baseline

  2. Apnea-hypopnea index (AHI)

    Apnea-hypopnea index (AHI) an index used to describe the number of apneas experienced during sleep. It is calculated by (Number of hours of sleep/Number of Apneas or hypopneas). This value will then be graded on a scale from Normal (\<5) to Severe (\>30).

    Time frame: Day 15, Day 29, and Day 42

  3. International Physical Activity Questionnaire

    International Physical Activity Questionnaire is a 0-10 visual analog scale to assess self-reported sleep quality

    Time frame: Baseline and Day 42

Secondary outcomes

  1. 24-hour blood pressure

    Blood pressure will be monitored for 24 hours and reported as mm/Hg

    Time frame: Baseline and Day 42

  2. Blood Pressure

    Blood Pressure will be reported as mm/Hg

    Time frame: Baseline, Day 22, and Day 42

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Apr 2028, 17 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2026
First posted
May 6, 2026
StartEst.
Nov 2026
Primary completionEst.
Apr 2028
CompletionEst.
Apr 2028
Last update
Sep 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07570953
Lead sponsor
Mayo Clinic
Responsible party
Virend Somers, MD, PhD (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
May 6, 2026
Start date
Nov 2026 (estimated)
Primary completion
Apr 2028 (estimated)
Completion
Apr 2028 (estimated)
Last update
Sep 18, 2026

Study contacts

Nick Wozniak
Contact
wozniak.nicholas@mayo.edu
507-255-8794
Virend Somers, M.D., Ph.D.
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dronabinol

Start the discussion